Pooled data from 3 phase III clinical trial shows that the addition of neoadjuvant carboplatin to chemotherapy improves outcomes for patients with early-stage triple-negative breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback